commitment

UBS maintains a target price of HK$52.6 and a "Buy" rating on Tigermed (03347).

A commitment by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.

瑞銀發報告指,維持泰格醫藥(03347)52.6港元目標價以及「買入」評級。
stockintelligencenewsPublished 2026-11-11 Read source

Discussion

0/2000

Related claims

UBS maintains a target price of HK$52.6 and a "Buy" rating for Tigermed (03347).瑞銀 · commitmentAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.瑞銀 · statementAfter the privatization is completed, Tigermed plans to acquire Frontage's non-target business in mainland China at a preliminary valuation of about US$205.5 million; the target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; Frontage founder Li Song and related trusts may acquire the overseas non-target business at a preliminary valuation of about US$84.4 million.瑞銀 · statementTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.瑞銀 · statementTigermed also plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% may be used for dividends or share buybacks.瑞銀 · commitmentIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.瑞銀 · prediction

More claims by 瑞銀

All claims by 瑞銀